Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Kenneth David Miller"'
Autor:
Nancy Corbitt, Lindsey Hertsenberg, Mary McQuaige, Paula Rosenblatt, Jungmin Yoon, Kendall Powell, Nick Jaidar, In Seo La, Shijun Zhu, Hyojin Son, Karen E Wickersham, Eun-Shim Nahm, Kenneth David Miller
Publikováno v:
Oncology Nursing Forum. 46:572-584
Objectives To evaluate an interactive electronic Cancer Survivorship Patient Engagement Toolkit (CaS-PET) using a single-group pre-/post-test design. Sample & setting 30 cancer survivors with a mean age of 56.5 years (SD = 13.6) were recruited from t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::98d6841d425ccd3877dd77fe32192e14
https://doi.org/10.1188/19.onf.572-584
https://doi.org/10.1188/19.onf.572-584
Publikováno v:
Case Reports in Oncological Medicine, Vol 2018 (2018)
Case Reports in Oncological Medicine
Case Reports in Oncological Medicine
A 64-year-old man, with history of micropapillary thyroid cancer and epidermal growth factor receptor-positive lung adenocarcinoma with no evidence of active disease for 3 years after chemotherapy and radiation on erlotinib, presented with fatigue, n
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7fc5f899cde7c4f272d0914967f5a32f
https://doi.org/10.1155/2018/2349021
https://doi.org/10.1155/2018/2349021
Autor:
Julio Oliveira, Kenneth David Miller, Christian Rolfo, Katherine A. Scilla, Christian Caglevic, Luis Corrales
Publikováno v:
Advances in Experimental Medicine and Biology ISBN: 9783030025045
The management of Non-Small Cell Lung Cancer (NSCLC) has changed dramatically in the last 10 years with an increase in the understanding of the biology and with the development of new and multiple treatments. Chemotherapy being the first systemic tre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e4555ff07fee3d68a29e09f56175ba33
https://doi.org/10.1007/978-3-030-02505-2_3
https://doi.org/10.1007/978-3-030-02505-2_3
Autor:
Rohit Gosain, Rahul Gosain, Shruti Bhandari, Amitoj Gill, Kenneth David Miller, Joseph R Abraham, Gurkirat Gill
Publikováno v:
American journal of clinical oncology. 41(10)
BACKGROUND Follow-up cancer care is important for patients who have received IV chemotherapy but some patients discontinue their care and are lost to follow-up (LFU) at the cancer center where they were treated. The purpose of this study was to deter
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1cfdbe8cf53c90f689c2302a587051f4
https://pubmed.ncbi.nlm.nih.gov/29028642
https://pubmed.ncbi.nlm.nih.gov/29028642
Autor:
Jeanne Phelps, Alexis Solis, Kenneth David Miller, Marvin J. Feldman, James F. Barter, Wanda Bell-Farrell, Corilynn Hughes, Lyudmila Kalnitskaya, Frederick Min, Michael A. Tangrea, Christine Wade, Sujana Lalagari
Publikováno v:
Journal of Clinical Oncology. 37:5567-5567
5567 Background: Hormonal therapy has limited activity in gynecologic (Gyn) cancer treatment. mTOR inhibitors plus aromatase inhibitors (AI's) improve the response rate and response duration in breast cancer patients. We studied this combination in h
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fd200bcc33075c83956ceeb6fc1bfe8d
https://doi.org/10.1200/jco.2019.37.15_suppl.5567
https://doi.org/10.1200/jco.2019.37.15_suppl.5567
Autor:
Søren M. Bentzen, Michael L. Adashek, Joseph Friedberg, Kenneth David Miller, Abigail Chan, Melissa Culligan, Tamara Khashab
Publikováno v:
Journal of Clinical Oncology. 37:8533-8533
8533 Background: Baseline neutrophil-lymphocyte ratio (NLR), a surrogate marker for systemic inflammation and immunosuppression, is a well-established prognostic marker in non-small cell lung cancer (NSCLC). This study tests if interim NLR is prognos
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::30e393af988d12e8e4234f738460fcba
https://doi.org/10.1200/jco.2019.37.15_suppl.8533
https://doi.org/10.1200/jco.2019.37.15_suppl.8533
Autor:
Kenneth David Miller, Michael E. Kallen, Joseph S. Friedberg, Michael L. Adashek, Melissa Culligan, Tamara Khashab, Rachel Fanaroff, Johnathan Heath, Abigail Chan
Publikováno v:
Journal of Clinical Oncology. 37:e20064-e20064
e20064 Background: Malignant Mesothelioma (MM) is an aggressive malignancy with survival of 4-12 mo. without treatment and 10% 5-year survival. The response of patients with MM to immunotherapy has increased interest in the tumor immune microenvironm
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e43c881df30797d762a4df9e863a6da9
https://doi.org/10.1200/jco.2019.37.15_suppl.e20064
https://doi.org/10.1200/jco.2019.37.15_suppl.e20064
Publikováno v:
The Cancer Journal. 19:438-443
Advances in medical care and increasing prevalence of noncommunicable illnesses such as cardiovascular disease and cancer had raised concerns about respecting the patients' dying wishes as early as 1938, when the Euthanasia Society of America was for
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cee0b51bde8743048d4c79131757444b
https://doi.org/10.1097/01.ppo.0000434393.56929.c8
https://doi.org/10.1097/01.ppo.0000434393.56929.c8
Publikováno v:
American journal of clinical oncology. 40(6)
The majority of the cancer survivors in the United States are 5 or more years beyond their diagnosis. The follow-up care of these individuals remains a major concern for survivors and for the cancer care system. The purpose of this study was to chara
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::886457ed6bac3abf840275331da32050
https://pubmed.ncbi.nlm.nih.gov/26359697
https://pubmed.ncbi.nlm.nih.gov/26359697
Autor:
Kenneth David Miller
Publikováno v:
The Cancer Journal. 14:358-360
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::52008f0830e1bee903228feddbe1befd
https://doi.org/10.1097/ppo.0b013e31818f046c
https://doi.org/10.1097/ppo.0b013e31818f046c